New treatment for a type of brain cancer in children
Official title: Nanoformulated small molecule immunotherapy for SHH medulloblastoma
Funded at Univ of North Carolina Chapel Hill · NIH-11004378 · Data updated 2026-11-12
This study is testing a new treatment for children with SHH medulloblastoma, a type of brain cancer, using a special drug that helps the immune system fight the cancer while aiming to cause fewer side effects than current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $349,875 |
| NIH project number | 5R01NS125073-04 |
| Project ID | NIH-11004378 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with SHH medulloblastoma who are undergoing treatment or have had recurrent disease.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with SHH medulloblastoma may not benefit from this research.
What this research studies
This research focuses on developing a new immunotherapy using nanoformulated small molecules to treat SHH medulloblastoma, a type of brain cancer in children. The approach aims to enhance the effectiveness of treatment while reducing the severe side effects associated with current therapies. By utilizing the body's immune system, the researchers hope to create a safer and more effective option for patients. The study will evaluate a specific drug, resiquimod, which targets immune cells in the tumor environment to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for children with SHH medulloblastoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous studies have shown promise in using immunotherapy for various cancers, indicating potential success for this novel approach in treating SHH medulloblastoma.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Sokolsky-Papkov, Marina — Univ of North Carolina Chapel Hill
- Study coordinator: Sokolsky-Papkov, Marina
Related research
Other NIH-funded projects on the same topics.
-
Immunotherapy for high-risk pediatric brain cancer using systems immunology
A program to understand why a dangerous form of childhood brain cancer resists immunotherapy and to develop new immune-based treatments for kids with Group 3 medulloblastoma.
-
Nanoparticle immune treatment for SHH‑subtype medulloblastoma
This project tests a tiny‑particle version of an immune drug designed to help children with SHH‑subtype medulloblastoma live longer with fewer lifelong side effects.
-
Immune-based treatments for aggressive Group 3 medulloblastoma
Working to unlock the immune system to create new treatments for children with high-risk Group 3 medulloblastoma.
-
Understanding how to improve immunotherapy for aggressive brain tumors in children
This study is looking at a tough type of brain tumor in kids called high-risk Group 3 medulloblastoma, and it's trying to find out how these tumors hide from the immune system so that new treatments can be created to help the immune system fight them better.
-
Using exosomes to improve immunotherapy for brain tumors in children
This study is testing a new treatment for children with medulloblastoma, a type of brain cancer, by using tiny particles from immune cells to help the body’s immune system fight the tumor more effectively while aiming to reduce side effects from standard treatments.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.